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ABSTRACT
Objective: The present study was designed to investigate the protective effect of Zileuton and MK-886 against hepatic damage induced by doxorubicin.
Methods: A total of 30 healthy adult male albino rats were randomized and rats were divided into five groups, six animals in each: Control negative 
group, Vehicle group: Rats were given ethanol i.p., Dx group: Doxorubicin (15 mg/kg), Mk group: Mk-886-treated rats given 0.6 mg/kg of Mk-886 
i.p, and Z group: Zileuton-treated rats given zileuton 10 mg/kg i.p. Biochemical tests of the serum for ASAT and ALAT level were estimated. Serum 
glutathione (GSH) concentrations (µg/ml) were determined using GSH ELISA Kit, while serum malondialdehyde (MDA) concentrations (ng/ml) were 
determined using MDA ELISA Kit. Livers were removed from each rat and fixed in 10% neutral-buffered formalin and embedded in paraffin for 
histopathological studies.
Results: MK- and zileuton-treated groups showed higher GSH levels and lower MDA levels as compared with Dx-treated group. MK-886 associated 
with significant p<0.05 decreased the liver enzymes in comparison with doxorubicin-treated rats. Zileuton showed insignificant (p>0.05) changes. 
The liver tissues that treated with Dx only showed several histopathological changes such as moderate sinusoidal dilation, vacuolation, mild-to-
moderate hepatocyte necrosis/degeneration and inflammatory cell infiltration, and severe congestion. Liver tissues that treated by zileuton with Dx 
showed sinusoidal dilation, vacuolation, mild congestion, and inflammatory cell infiltration, while those treated with Mk-886 plus Dx showed nearly 
normal liver pathophysiology.
Conclusion: It has been concluded that Zileuton and MK-886 have protective effects against hepatic damage induced by doxorubicin.
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INTRODUCTION
Doxorubicin is a potent anthracycline anticancer drug used to treat 
different types of malignancies [1] such as breast cancer, leukemia, 
and AIDS-related Kaposi’s sarcoma [2,3]. Further, it is also used 
in the treatment of cancers of bladder, testes, ovaries, lung, cervix, 
prostate, and Ewing’s sarcoma [4]. The clinical effectiveness of DXR in 
the management of a wide range of malignant diseases is influenced 
by various dose-limiting adverse effects such as hepatotoxicity, 
nephrotoxicity, and cardiomyopathy [5-7]. Systemic toxicity is occurring 
clinically at doses less than the therapeutic doses [8]. The toxicity is 
started at imbalance the free radical production by two pathways: 
Enzymatic pathway using a respiratory chain of the mitochondrial and 
a non-enzymatic pathway occurred by utilizing iron [9]. The apoptotic 
processes are increasing in hepatic tissues after taking one dose of 
DOX [10]. The DOX dose increased lipid peroxidation in mitochondria 
and microsomes in the liver tissue, particularly with iron ions [11]. The 
DOX causes hepatotoxicity such as steatosis, vascular damage, and focal 
damage in hepatocytes [12].
Leukotrienes (LT) considered as a pro-inflammatory lipid mediator that 
is produced by the action of 5-lipoxygenase enzyme on arachidonic acid 
[13]. Zileuton is an inhibitor of 5-lipoxygenase activity if takes it orally 
and so that zileuton can block all products of the 5-lipoxygenase (Cys-
LTs and LTB4). It is used to ameliorate the symptoms of asthma [14,15]. 
MK-886 (investigational compound) is an inhibitor of leukotriene 
production in vitro and in vivos. Moreover, this agent inhibits the 
activation and translocation of 5-lipoxygenase by inhibiting leukotriene 
biosynthesis and by an indirect pathway through the binding of a 
membrane-bound 5-lipoxygenase-activating protein (FLAP) [16].
MATERIALS AND METHODS
Animals
A 30 healthy adult male albino rats with average weight (230±30 g) 
were housed in animal’s house of the College of Pharmacy, University 
of Al-Qadisiyah, Iraq. Under 12 hr. light/12 hr. dark at 25C, rats were 
fed. Rats were fed standard rodent chew diet and tap water. This study 
continued for 3 days. Protocol of the current research was approved 
by the Institute Review Board at the College of Pharmacy, University of 
Al-Qadisiyah, Iraq.
Materials
Doxorubicin was used (50 mg in 25 ml, EBEWE Pharma Ges. m.b.H., 
4866-A Unterach., Austria.), MK-886 powder was from Santa Cruz 
Biotechnology, Inc. (Lot H3116), and zileuton powder was from Santa 
Cruz Biotechnology, Inc. (Lot A2513).
Experimental design






before doxorubicin administration [16].
•	 Z	group:	Zileuton-treated	rats	given	zileuton	10	mg/kg	i.p	30	min	
before doxorubicin administration [18].
After 3 days, all rats were anesthetized by intraperitoneal injection of 
thiopental sodium (70 mg/kg) [19].
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Assay of serum ALAT and ASAT concentrations
Blood was drawn and quickly put in gel separator tubes to clot at 25°C. 
The samples were centrifuged for 10 min at 3000 rpm (30°C). The 
supernatant layer of the serum appears and transfers to another clean 
tube.	Then,	samples	were	 frozen	at	−30°C	 for	 long-term	preservation	
for making biochemical tests of the serum for the estimation of ASAT 
and ALAT level.
Assay of glutathione (GSH) and malondialdehyde (MDA) 
concentrations
Serum GSH concentrations (µg/ml) were determined using GSH ELISA Kit 
Catalog No: E-EL-0026 (96T) that obtained from Elabscience Biotechnology 
Inc., while serum MDA concentrations (ng/ml) were determined 
using MDA ELISA Kit Catalog No: E-EL-0060 (96T) that obtained from 
Elabscience Biotechnology Inc. Both GSH and MDA assay procedures were 
done according to the procedures that mentioned in the kit leaflet.
Histopathological examination of the liver
Livers were removed from each rat and fixed in 10% neutral buffered 
formalin and embedded in paraffin for histopathological studies.




4. +++ (severe) [20].
Statistical analysis
The samples data were submitted to the analysis by SPSS program 
12.0 edition using one-way analysis of variance and then submitted for 
Dunnett’s test at p<0.05.
RESULTS
Effect of zileuton and MK-886 treatment on liver function 
biomarkers
As shown in Fig. 1, doxorubicin caused a significant (p<0.05) increased 
serum liver enzyme (ASAT and ALAT) concentration when compared 
with negative control group. MK-886 associated with significant p<0.05 
decreased the liver enzymes in comparison with doxorubicin-treated 
rats. Zileuton showed insignificant (p>0.05) changes while vehicle 
group did not affect study parameters.
Effect of zileuton and MK-886 treatment on GSH and MDA levels
As shown in Fig. 2 negative control and vehicle groups presented with 
normal GSH and MDA values, a doxorubicin-treated group associated 
with significant (p<0.05) decreases GSH levels and increases MDA 
levels when compared with negative control group. MK- and zileuton-
treated groups showed higher (p<0.05) GSH levels and lower (p<0.05) 
MDA levels as compared with Dx-treated group.
Zileuton and MK-886 treatments on liver histopathology
Table 1 shows the control and vehicle groups in normal liver 
architecture (Fig. 3a and b). The liver tissues that treated with Dx 
only showed several histopathological changes such as moderate 
sinusoidal dilation, vacuolation, mild-to-moderate hepatocyte 
necrosis/degeneration and inflammatory cell infiltration (n=4), and 
severe congestion (Fig. 3c-f). Liver tissues that treated by zileuton 
with Dx showed sinusoidal dilation, vacuolation, mild congestion, and 
inflammatory cell infiltration as shown in Fig. 3g, while those treated 
with Mk-886 plus Dx showed nearly normal liver pathophysiology 
(Fig. 3h).
Fig. 2: Oxidative markers in rats. (a) Rat GSH ELISA means concentration in µg/ml, (b) Rat MDA ELISA mean concentration in ng/ml
a b
Fig. 1: Liver function test. (a) Mean serum ALAT concentration U/L (b) Mean serum ASAT concentration U/L
ba
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DISCUSSION
Dx is a drug used for the treatment of cancer, especially leukemia and 
solid tumors. Therapy by Dx has limited toxicity as compared with 
quinone anthracyclines [21]. The free radical formation was thought 
that it was produced by Dx administration [22]. The hepatotoxicity is 
occurring by treatment with Dx in many animals [23]. The significant 
steatosis, the vascular damage, and focal damage in the liver cell are 
appearing after Dx administration [24]. 20 mg/kg of Dx is increased 
ALAT level in serum double normal in mice [25]. These results are the 
same in our study. However, there are several changes in enzyme level 
(ASAT and ALAT) after injection of DX dose alone. DX can increase the 
levels of ASAT and ALAT in serum and that agree with another study 
[26]. Shiyun Pu shows pharmacological inhibition or deletion of 5-LO 
prevented paracetamol increased serum ALAT and ASAT values and 
hepatic necrosis [27]. Gul Daglar used the measurement of the ALAT 
concentration as a marker for the detection of parenchymal cell injury 
of the liver. The ALAT levels increase significantly after injection. 
Furthermore, MK-886 treatment increases in ALAT concentration in 
hepatic I/R when compared with I/R group, decreasing of the ALAT 
concentration is an indicator of liver protection against hepatic I/R 
injury [28].
Our results demonstrated that MK- and zileuton-treated groups 
cause higher GSH levels and lower MDA levels when compared with 
Dx-treated group. Several local types of research demonstrated that 
zileuton associated with higher GSH and lower MDA levels when 
compared with the induced group [14,15]. Tu et al. found that zileuton 
causes decreasing MDA level in rats. The selective 5-LOX inhibitor, 
zileuton,	inhibited	NF-κB	activation,	and	12	reduced	the	activation	and	
expression	of	iNOS.	Furthermore,	NF-κB	can	regulate	iNOS	expression	
and some inflammatory mediators [29]. No supported data are available 
for the effect of Mk-886 on oxidative markers.
Furthermore, our study showed that those treated with zileuton plus 
Dx liver tissues showed vacuolation, inflammatory cell infiltration, 
and sinusoidal dilation with mild congestion, while those treated with 
Mk-886 plus Dx showed nearly normal liver pathophysiology. In high-
fat-diet-induced non-alcoholic fatty liver disease (NAFLD), Kuifen 
concluded that inhibitor zileuton and inhibition of 5-lipoxygenase 
progression model and so AA/5-LOX pathway stimuli the progression 
of NAFLD, which could reverse by zileuton administration [30].
CONCLUSION
Through our finding, we can conclude that Zileuton and MK-886 have a 
protective effect against hepatic damage induced by doxorubicin.
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